Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/57598
Title: | Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study | Authors: | Sunar Yayla, Emine Nur Gezgin Yıldırım, Deniz Adıgüzel Dündar, Hatice Adrovic, Amra Akboru, Elifsu Gözde Aktay Ayaz, Nuray Aliyev, Emil Avar Aydın, Pınar Özge Aydın, Fatma Baba, Özge Bağlan, Esra Bora Makay, Balahan Bozkaya Yücel, Burcu Çakan, Mustafa Çelikel, Elif Demir, Ferhat Demir, Selcan Demirkan, Fatma Gül Ekici Tekin, Zahide Esmeray Şenol, Pelin Guliyeva, Vefa Güngörer, Vildan İşgüder, Rana Kalyoncu, Mukaddes Karadağ, Şerife Gül Kısaoğlu, Hakan Kışla Ekinci, Rabia Miray Kızıldağ, Zehra Kurt, Tuba Özdel, Semanur Özdemir Çiçek, Sümeyra Öztürk, Kübra Polat, Merve Cansu Sezer, Müge Sönmez, Hafize Emine Sözeri, Betül Şener, Seher Taşkın, Sema Nur Türkuçar, Serkan Ünsal, Erbil Yıldız, Çisem Bakkaloğlu, Sevcan A. |
Keywords: | Rituximab Survey Adverse events Vaccination Pediatric rheumatology Rheumatoid-Arthritis Therapy Safety Management |
Publisher: | Springer | Abstract: | Rituximab (RTX) is a chimeric monoclonal antibody that targets the CD20 antigen on B cells and is used in various autoimmune disorders. In this study, we aimed to measure the awareness of pediatric rheumatologists about the use of RTX through a survey. Between February and March 2023, a 42-question survey was sent via email to pediatric rheumatology specialists in Turkey. The participants were questioned for which diagnoses and system involvement they preferred to use RTX, which routine tests they performed, vaccination policy, and adverse events that occurred during or after infusion. Forty-one pediatric rheumatologists answered the survey. They prescribed RTX most frequently for systemic lupus erythematosus (87.8%) and ANCA-associated vasculitis (9.8%). Prior to the administration of RTX, 95% of clinicians checked renal and liver function tests, as well as immunoglobulin levels. The most frequently tested hepatitis markers before treatment were HBsAg and anti-HBs antibody (97.6%), while 85.4% of rheumatologists checked for anti-HCV. Clinicians (31.4%) reported that they postpone RTX infusion 2 weeks following an inactivated vaccine. Sixty-one percent of rheumatologists reported starting RTX treatment 1 month after live vaccines, while 26.8% waited 6 months. The most frequent adverse events were an allergic reaction during RTX infusion (65.9%), hypogammaglobulinemia (46.3%), and rash (36.6%). In the event of hypogammaglobulinemia after RTX treatment, physicians reported that they frequently (58.5%) continued RTX after intravenous immunoglobulin administration.Conclusions: RTX has become a common treatment option in pediatric rheumatology in recent years. Treatment management may vary between clinician such as vaccination and routine tests. What is Known:center dot During the course of rituximab therapy, clinicians should be attentive to specific considerations in pre-treatment, during administration, and in post-treatment patient monitoring.What is New:center dot There are differences in practice among clinicians in the management of RTX therapy. These practice disparities have the potential to impact the optimal course of treatment.center dot This study highlights that standardized guidelines are needed for RTX treatment in pediatric rheumatology, particularly for vaccination policies and routine tests. | URI: | https://doi.org/10.1007/s00431-024-05654-9 https://hdl.handle.net/11499/57598 |
ISSN: | 0340-6199 1432-1076 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.